UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 192

Sortiert nach

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.992-1000

2019

Volltextzugriff (PDF)

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1660-1666

2009

Volltextzugriff (PDF)

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4741-4746

2009

Volltextzugriff (PDF)

Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia

Journal of clinical oncology, 2002-02, Vol.20 (3), p.656-664

Giles, F. J.

2002

Volltextzugriff (PDF)

Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer

Journal of clinical oncology, 2004-03, Vol.22 (5), p.864-871

2004

Volltextzugriff (PDF)

Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia

Journal of clinical oncology, 2001-02, Vol.19 (3), p.762-771

2001

Volltextzugriff (PDF)

5-Formyltetrahydrofolate Regulates Homocysteine Remethylation in Human Neuroblastoma

The Journal of biological chemistry, 1997-02, Vol.272 (8), p.4729-4734

1997

Volltextzugriff (PDF)

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

Clinical cancer research, 2006-04, Vol.12 (7), p.2158-2165

2006

Volltextzugriff (PDF)

Implementing DPYD2A Genotyping in Clinical Practice: The Quebec, Canada, Experience

The oncologist (Dayton, Ohio), 2021-04, Vol.26 (4), p.e597-e602

2021

Volltextzugriff (PDF)

The New Dioxolane, (-)-2′-Deoxy-3′-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts

Clinical cancer research, 2000-04, Vol.6 (4), p.1574-1578

2000

Volltextzugriff (PDF)

Implementing DPYD2A genotyping in clinical practice, the Quebec experience

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.650-650

2019

Volltextzugriff (PDF)

Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2002-01, Vol.20 (1), p.96-109

de Bono, J. S.

2002

Volltextzugriff (PDF)

Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT098-CT098

2017

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days

Journal of clinical oncology, 2002-05, Vol.20 (10), p.2567-2574

2002

Volltextzugriff (PDF)

Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

American journal of clinical oncology, 2016-12, Vol.39 (6), p.609-613

2016

Volltextzugriff (PDF)

Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics

Clinical cancer research, 2004-11, Vol.10 (22), p.7692-7702

2004

Volltextzugriff (PDF)

Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

American journal of clinical oncology, 2013-06, Vol.36 (3), p.239-243

2013

Volltextzugriff (PDF)

The Pharmacology and Clinical Use of Methotrexate

The New England journal of medicine, 1983-11, Vol.309 (18), p.1094-1104

1983

Volltextzugriff (PDF)

Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e14706-e14706

2012

Volltextzugriff (PDF)

Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study

Clinical lymphoma, myeloma and leukemia, 2011-10, Vol.11 (5), p.433-438

2011

Volltextzugriff (PDF)

Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4105-4105

2012

Volltextzugriff (PDF)

Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells

The Journal of clinical investigation, 1982-08, Vol.70 (2), p.351-360

1982

Volltextzugriff (PDF)

Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7217-7224

2001

Volltextzugriff (PDF)

Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML

Blood, 2008-11, Vol.112 (11), p.764-764

2008

Volltextzugriff (PDF)

Human 5,10-methenyltetrahydrofolate synthetase

Methods in Enzymology, 1997, Vol.281, p.162-170

Jolivet, Jacques

1997

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(157)
Mit Volltextzugriff
(179)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia

Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer

Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced Leukemia

5-Formyltetrahydrofolate Regulates Homocysteine Remethylation in Human Neuroblastoma

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

Implementing DPYD2A Genotyping in Clinical Practice: The Quebec, Canada, Experience

The New Dioxolane, (-)-2′-Deoxy-3′-oxacytidine (BCH-4556, Troxacitabine), Has Activity against Pancreatic Human Tumor Xenografts

Implementing DPYD2A genotyping in clinical practice, the Quebec experience

Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies

Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies

Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days

Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics

Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

The Pharmacology and Clinical Use of Methotrexate

Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC)

Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study

Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells

Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines

Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML

Human 5,10-methenyltetrahydrofolate synthetase

Suchergebnisse filtern